Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.54 |
| ▸ | ACACB | O00763 | 4/20 | 0.48 |
| ▸ | ACACA | Q13085 | 3/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.43 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.42 |
| ▸ | SCD | O00767 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6539604 | 0.88 | MEN1 (0.53) | MEN1KMT2APABPC1ACACBACACA | |
| SCHEMBL6540380 | 0.87 | MEN1 (0.52) | MEN1KMT2APABPC1ACACBACACA | |
| SCHEMBL6540335 | 0.87 | RAB9A (0.52) | ACACBMAOBNR4A1NR4A2NR4A3 | |
| SCHEMBL6258849 | 0.87 | RAB9A (0.52) | ACACBMAOBNR4A1NR4A2NR4A3 | |
| SCHEMBL6231187 | 0.87 | MEN1 (0.55) | MEN1KMT2APABPC1ACACBACACA | |
| SCHEMBL6206366 | 0.82 | MEN1 (0.56) | MEN1KMT2APABPC1ACACBACACA | |
| Hydrochloric Acid SCHEMBL6207662 | 0.81 | MEN1 (0.55) | MEN1KMT2APABPC1ACACBACACA | |
| SCHEMBL6208425 | 0.78 | MEN1 (0.56) | MEN1KMT2APABPC1ACACBACACA | |
| SCHEMBL6539764 | 0.77 | MEN1 (0.50) | MEN1KMT2APABPC1ACACBACACA | |
| SCHEMBL6207531 | 0.76 | NPC1 (0.51) | MEN1KMT2AACACBMAOBNR4A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040157891-A1 | Inhibitor of cox | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157891-A1 | Inhibitor of cox | PTGS1, PTGS2, PTGES2 | MEN1 4420/4885KMT2A 3081/4885PABPC1 2765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.